Developing and commercializing novel drugs to treat viral infections.
Business Model:
Revenue: $0
Employees: 5,001-10,000
Pharmasset was acquired by
Gilead Sciences.
The acquisition happend on 2011-11-21.
Details of the transaction were not public
Address:
City: Princeton
State: New Jersey
Zip:
Country: United States
Pharmasset Inc is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Their primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus, or HBV, hepatitis C virus, or HCV and human immunodeficiency virus, or HIV. Their research and development efforts focus on a class of compounds known as nucleoside analogs, which act to inhibit the natural enzymes required for viral replication. They are currently focusing on three product candidates, two of which they are developing themselves and one of which they are developing with a strategic partner: • Clevudine, for the treatment of HBV, expected to enter Phase 3 registration clinical trials in the second calendar quarter of 2007; • R7128, a pro-drug of PSI-6130 for the treatment of HCV, in a Phase 1 clinical trial; and • Racivir, for the treatment of HIV, in a Phase 2 clinical trial.
Contact Phone:
Contact Email:
Listed Exchange:
NASDAQ
IPO Date:
4/27/2007
Ticker Symbol:
VRUS
IPO Price:
$9/share
Amount Raised:
$45M
Opened: -/share
EBITDA | - |
Total Cash | - |
Total Debt | - |
Total Revenue | - |
Total Profit (Gross) | - |
PE Ratio | - |
Announced Date | Company | Transaction | Money Raised |
---|
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 6/1998 | Series A | 1 | $4.5M |
DuPont DuPont |
3/2001 | Series C | 2 | $7.4M |
Techno Venture Management MPM Capital MPM Capital Techno Venture Management MPM Capital MPM Capital |
10/1999 | Series B | 1 | $3.9M |
MPM Capital MPM Capital MPM Capital MPM Capital |
8/2004 | Series D | 6 | $40M |
MDS Capital MPM Capital Bank of America Securities Techno Venture Management CDIB BioScience Ventures Burrill and co Burrill and co MDS Capital MPM Capital Bank of America Securities Techno Venture Management CDIB BioScience Ventures Burrill and co Burrill and co |
7/2008 | Post-IPO Equity | $25.9M |
---|
Announced Date | Name | Price |
---|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|